Core Viewpoint - The article announces the extension of the application deadline for the Global MedTech Innovation Awards to June 20, 2025, to allow more time for participants to prepare their submissions and showcase their innovations in the medical technology field [1]. Group 1: Event Overview - The Global MedTech Conference 2024 will take place on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, with an expected attendance of around 500 participants from various sectors including government, hospitals, leading enterprises, startups, investment institutions, and research institutes [5]. - The conference aims to highlight and award groundbreaking achievements in medical technology, with a focus on innovation, application, and service contributions [4][8]. Group 2: Award Categories - The awards include: 1. 2025 Global MedTech Innovation Award 2. 2025 Global MedTech Clinical Application Award 3. 2025 Global MedTech Service Contribution Award 4. 2025 Global MedTech Supply Chain Excellence Award 5. 2025 Global MedTech Innovation & Translation Award (Individual) [4][8]. Group 3: Application Process - The application phase is open from now until June 20, 2025, followed by a review phase from June 21 to June 29, with results to be announced between June 30 and July 4 [11]. - Participants must submit specific documents including a personal resume, a summary of research achievements, and any relevant supporting materials [13].

Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end intelligent diagnostic equipment, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1] Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical application [1][4] - The first conference, Global MedTech Conference 2024, was organized by Siyu [2] Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Innovation Application Award [3][7] - The awards aim to honor cutting-edge technological advancements, successful results transformation, and outstanding services in the medical technology field [3] Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5] - Other topics will cover experiences in the intersection of medicine and engineering, breakthroughs in AI-assisted diagnosis and digital therapy, and insights into technology directions and company profiles attracting domestic and foreign capital [5] Group 4: Participation and Submission Guidelines - The awards are open to medical device and digital medical technology companies with innovative products or platform technologies that demonstrate originality, advancement, and potential for large-scale industrialization [6] - Submission for the awards is open until May 31, 2025, with a review phase from June 1 to June 15, 2025, and results to be announced between June 16 and June 22, 2025 [10]

2025年3月25日，海易特医疗科技(上海)有限公司与上海交通大学医学院附属上海儿童医学中心在 儿童医学中心的张江院区共同举办了"儿童肿瘤康复机器人系统联合开发项目"启动会。此次项目标志着 双方在儿童肿瘤康复领域的技术创新与临床应用的深度合作正式启航。 启动会现场，上海儿童医学中心张江院区的小儿外科肿瘤外科主任顾松率先发表致辞。他首先对来 到启动会的各位嘉宾表示热烈欢迎，随后他对医学中心进行了简单介绍，他提到上海儿童医学中心是三 个国家儿童医学中心之一，张江院区在治疗儿童肿瘤方面无论在规模上，还是技术上都是顶尖的，针对 院内儿童恶性肿瘤彻底治愈率有着非常高的水平。本次也由衷地希望与海易特公司合作研发康复机器人 系统来解决儿童肿瘤患者肌无力、肌少症等康复问题。临床研究中心的王友俊主任提到：儿童医学中心 在小儿的治疗、康复、心理辅导方面有着全周期的管理模式，他对海易特技术的专业性及康复行业的热 情表示非常认可，并希望通过双方共同的努力，未来将儿童医学中心建造成更有温度的医院。 随后，海易特医疗科技的董事长范卫东也进行了发言，他表示公司会尽最大努力将技术及专家力量 投入到设备的研发中，加快推进康复机器人系统的落地， ...

北极光创投创始管理合伙人邓锋（右二）在上市仪式现场。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，脑动极光医疗科技有限公司（以下简称"脑动极光"）于2025年1月8日正式 以"6681"为股票代码在港交所主板挂牌上市，成为"中国数字疗法第一股"。 截至10:00，脑动极光报于每股3.48港元，较发行价上涨8.07%，市值超44亿港元。 成立于2 012 年的 脑动极光 作为 中国认知障碍数字疗法市场的资深参与者，也是中国首家将脑科 学与先进的人工智能技术相结合开发医疗级数字疗法产品的公司，产品管线涵盖由血管疾病、神经退 行性疾病、精神疾病及儿童发育缺陷等诱发的广泛的认知障碍的测评和干预。 截至2024年12月21日，脑动极光的核心产品「脑功能信息管理平台软件系统」已就四种主要类型认 知障碍的八种适应症实现商业化，且正在开发其他几种认知障碍适应症。截至同日，脑动极光有另外 三款产品已于中国获得监管批准（基本认知能力测验软件（BCAT）、认知能力辅助筛查评估软件 （SAS）及阅读障碍辅助筛查评估软件（DSS））、另有一款产品已于欧盟获得监管批准（认知 ...